Objective: We hypothesized that body mass index (BMI) and DNA variants would predict age at menarche in polycystic ovarian syndrome (PCOS). Subjects: Subjects aged 18-45 years with PCOS defi ned by the National Institutes of Health criteria (n = 522) and controls with regular menstrual cycles and no hyperandrogenism (n = 472) were studied. Methods: Age at menarche was compared between PCOS cases and controls and examined as a function of multiple parameters.
Introduction
Girls with polycystic ovarian syndrome (PCOS) exhibit a wider range in age at menarche than control subjects (1) .
Therefore, the timing of menarche may provide supporting information to a clinician attempting to make a diagnosis of PCOS in adolescence. However, the age at menarche in women with PCOS may be earlier or later than controls based on several factors that have opposing infl uence. The waves of progressive follicle development that occur during puberty (2) , which are accompanied by estradiol increases, withdrawal bleeding, and eventual ovulatory follicle development, may be delayed if the follicle arrest characteristic of PCOS begins in adolescence, resulting in a later age at menarche despite some breast development from estradiol production by the arrested follicles. As such, girls who are later diagnosed with PCOS can present with primary amenorrhea (3) . On the contrary, girls who develop PCOS may experience premature pubarche, and in a subset of these girls, specifi cally those born small for gestational age, menarche may be earlier (4) . Further, higher weight is associated with earlier age at menarche (5) , and many girls who go on to develop PCOS are overweight or obese at adolescence (6) . Evaluating the age at menarche in large groups of women with PCOS may help dissect these infl uences.
In addition to overweight and arrested follicle development, age at menarche in women with PCOS may be regulated by the genetic variants involved in normal menarche. The fi rst large genome-wide association studies identifi ed two chromosomal regions that are associated with age at menarche (7 -10) . Variants in or near LIN28B on chromosome 6 (rs314276-C, rs314277-C, and rs7759938-T) and on chromosome 9 (rs2090409-A) in a region in which a candidate gene has not yet been identifi ed (7 -10) have been associated with an earlier age at menarche. The role of genetic variants associated with age at menarche has not been examined in women with PCOS.
We hypothesized that women with PCOS would have an altered age at menarche compared with control subjects, infl uenced not only by weight but also by genetic variants. The hypothesis was tested in a large group of women with PCOS and controls of European ancestry.
Methods

Subjects
All subjects were US women of European ethnicity, screened at the same research hospital and between the ages of 18 and 45 years. Subjects with PCOS (n = 522) had oligomenorrhea ( < 9 menstrual periods per year) and clinical and/or biochemical evidence of hyperandrogenism, fulfi lling the National Institutes of Health criteria (11, 12) . Clinical hyperandrogenism was defi ned by an elevated Ferriman Gallwey score > 9 (13) or acne on the face or back. Biochemical hyperandrogenism was defi ned as testosterone > 2.8 nmol/L (63 ng/dL), dehydroepiandrosterone sulfate (DHEAS) > 1.16 μ moL/L (430 μ g/dL), or androstenedione levels > 13.3 nmol/L (3.8 ng/mL) (12) . Control subjects had regular menstrual cycles, 21-35 days, and no physical examination or biochemical evidence of hyperandrogenism (n = 472). Subjects were excluded for a personal history or evidence of late onset congenital adrenal hyperplasia (12) . All subjects had normal thyroid function and prolactin levels and a follicular phase follicle-stimulating hormone (FSH) level in the premenopausal range. Subjects were on no hormonal medication, except for stable thyroid hormone replacement.
Protocol
The study was approved by the Institutional Review Board of the Massachusetts General Hospital, and all subjects gave written informed consent. All PCOS subjects were studied > 10 days after their last menstrual period and after a 12 h fast (12) . Subjects underwent a detailed history using a standardized questionnaire; physical examination including measurement of waist circumference at the umbilicus and hip circumference at the widest diameter; a pelvic ultrasound (ATL HDI 1500, 5-MHz convex array transducer); and blood samples for lipids, glucose, insulin, gonadotropin, and sex steroid levels. An oral glucose tolerance test was performed, with blood sampling 2 h after a 75-g glucose load.
Age at menarche was reported by recall, along with other milestones of puberty, birth, and development information. Subjects were able to speak with parents if they did not know the answer to questions about birth or the neonatal period. The correlation between recorded age at menarche and recalled age after 23 -33 years was high in previous studies (r = 0.79, p < 0.001) (14) , which is a longer interval than that for a majority of subjects in the current study. Weight during adolescence was reported in weight groups; a previously validated questionnaire parameter (15) .
Assays
Serum luteinizing hormone (LH) and FSH were measured using a two-site monoclonal non-isotopic system (Axsym; Abbott Laboratories, Abbott Park, IL, USA) and expressed in IU per liter as equivalents of the Second International Reference Preparation 71/223 of human menopausal gonadotropins. Serum testosterone and androstenedione were measured using an RIA [Coat-a-Count; Diagnostic Products Corporation (DPC), Los Angeles, CA, USA]. 17-OH progesterone was measured by liquid chromatography-tandem mass spectrometry (Mayo Medical Laboratories New England, Wilmington, MA, USA). Sex hormone-binding globulin (SHBG) and insulin were measured using an immunochemiluminescent assay (Immulite 2000, DPC).
Genotyping
Variants previously associated with age at menarche at 6q21 rs314276, rs314277 and rs7759938 (7 -9) , and 9q31.2 rs2090409 (10) were selected. A panel of 152 markers informative for European, African American, and Latin ancestry were genotyped to control for false associations related to population stratifi cation (16 -18) . Patient DNA was isolated from whole blood. Genotyping was performed by primer extension of multiplex products with detection by MALDI-TOF mass spectroscopy using a Sequenom platform (Sequenom Corporation, San Diego, CA, USA). One single-nucleotide polymorphism (SNP), rs314276, failed with an ability to determine the genotype (call rate) in < 90 % . Fortyfour PCOS cases and 29 control samples failed with a call rate of < 90 % .
The remaining three age at menarche SNPs showed no departure from Hardy-Weinberg equilibrium (p > 0.001).
Statistical analysis
The proportion of women with PCOS and control subjects reporting categorical variables were compared using χ 2 analysis. Continuous data were log transformed for analysis. Phenotypic characteristics were compared between PCOS cases and controls using ANCOVA adjusting for age and body mass index (BMI) or two-way ANOVA to maintain BMI as a variable. The association of three age at menarche SNPs with PCOS in cases and controls was tested using χ 2 analysis. Log-transformed quantitative traits were compared by ANOVA across three genotype classes for each variant tested. Data were adjusted for age, BMI, and ancestry (16 -18) , and results are reported after correction for multiple testing by permutation analysis using 5000 permutations. A p-value < 0.05 was considered signifi cant after corrections.
Results
Neonatal parameters
Women with PCOS were more likely to report an early or late birth compared with control subjects (p = 0.005) ( Table 1 ) . There was no difference in reported birth order or birth weight, even when subjects with early or late birth were removed (p = 0.3), between PCOS and control subjects. Women with PCOS were less likely to have been breastfed (62 % vs. 75 % ; p < 0.001; PCOS vs. controls, respectively).
Puberty parameters
Women with PCOS were less likely to report development on time and more likely to report earlier and later pubertal development compared with peers. There were more women with PCOS than control subjects who reported age at menarche of 15 years or older (Table 1) . Within the PCOS group, there was an inverse correlation between current BMI and age at menarche (r = -0.32, p = 5 × 10
), pubarche ( -0.13, p = 0.04), thelarche ( -0.33, p = 1 × 10 − 9 ), and growth spurt (r = -0.23, p < 0.001), but not in control women (all p > 0.05). Therefore, data were adjusted for age and BMI. Women with PCOS reported an earlier age at pubarche on average than control subjects (Table 1) . Women with PCOS were also more likely to report irregular menses ( ≤ 9 menses per year) before the age of 18 years (79 % vs. 15 % , p < 0.001) and a lower number of cycles per year than control subjects (Table 1 ). There was an inverse correlation between the number of menses per year and age at menarche ( -0.21, p = 1 × 10 4 ).
Pubertal weight and age at menarche
Women with PCOS who were currently overweight ( ≥ 25 -26.9 kg/m 2 ) or obese ( ≥ 27 kg/m 2 ) were more likely to report that they were slightly or very overweight compared with peers at ages 5-9 years (42 % vs. 17 % ; current BMI ≥ 25 vs. < 25 kg/m 2 , respectively), 10-14 years (66 % vs. 22 % ), and 15-19 years (70 % vs. 18 % ) than women with PCOS whose BMI was currently < 25 kg/m 2 (all p < 0.001). Control women who were currently overweight or obese were also more likely to report that they were slightly or very overweight compared with peers at ages 5-9 years (28 % vs. 11 % ), 10-14 years (50 % vs. 16 % ), and 15-19 years (52 % vs. 11 % ) than women whose BMI was currently < 25 kg/m 2 (all p < 0.001). However, the proportion of control women who reported overweight and the overall number of women who were currently overweight or obese was lower than in women with PCOS (25 % vs. 64 % , p < 0.001).
Women with PCOS were more likely than controls to report that their weight was slightly higher or much higher than their peers at ages 5-9, 10-14, and 15-19 years (Table 2 ; all p < 0.01), and the proportion of subjects reporting their weight as much higher than their peers increased from the 5-to 9-year-old age group to the 10-to 14-year-old age group. In contrast, there was no difference in reported height compared with peers at the same ages between PCOS and control subjects (data not shown). Both current BMI ( β = -0.03, p = 0.009) and weight category at age 10-14 years ( β = -0.4, p < 0.001) correlated with age at menarche in women with PCOS. The weight category at age 10-14 years also predicted age at menarche in controls ( β = -0.5, p < 0.001), although current BMI did not ( β = -0.003, p = 0.9). Women with PCOS and controls who reported being thin compared with their peers at age 10-14 years had later menarche at age 14 or ≥ 15 years, whereas those who weighed slightly or much more than their peers at 10-14 years had a younger age at menarche (Figure 1 ). The expected differences in BMI, androgen, and gonadotropin levels and metabolic parameters were demonstrated between women with PCOS and controls (Table 3 ; *p < 0.001 between PCOS and control). In addition, control subjects were taller than women with PCOS. Overall, earlier menarche was associated with shorter stature, higher BMI, higher waist and hip circumference, lower SHBG and high-density lipoprotein (HDL), higher Ferriman Gallwey score, fasting insulin levels, and measurements of insulin resistance in women with PCOS and controls, and with lower hemoglobin A1c (HbA1C) in control women (Table 3 ). These relationships with age at menarche disappeared when controlled for BMI, with the exception of shorter height (p < 0.001), larger waist circumference (p = 0.02), and higher Ferriman Gallwey score (p < 0.01). There was no relationship among current androgen and gonadotropin levels, ovarian volume or follicle number, and age at menarche (Table 3) .
There was no relationship between genetic loci associated with menarche and PCOS status, including variants on chr 6 rs7759938 [odds ration (OR) 1.02, [0.8 -1.3; 95% confi dence interval (CI)], p = 0.9), rs314277 (OR 0.9, [0.7 -1.2; 95% CI], p = 0.5), and chr 9 rs2090409 (OR 1.13, [0.9 -1.4; 95% CI], p = 0.3). The rs7759938 T variant was associated with earlier age at menarche in all subjects and in women with PCOS alone (Table 4 ). The A variant at rs2090409 on 9q31.2 was associated with smaller waist circumference in control subjects (Table 4) . Taken together, age at menarche was predicted by a combination of PCOS status ( β = 0.512, p < 0.001), current BMI ( β = -0.0202, p = 0.01), reported weight group at age 10-14 years ( β = -0.432, p < 0.001) and genotype at rs7759938 ( β = 0.169, p = 0.02).
Discussion
Women with PCOS were more likely to report early and late development compared with their peers. The difference was explained by reported earlier pubarche and earlier or later menarche in women with PCOS. The timing of menarche was infl uenced by BMI, reported low or high weight compared with peers at ages 10 -14 years, and genotype at variant rs7759938 near LIN28B . The data suggest that age at menarche in women with PCOS is associated with identifi ed genetic variants controlling age at menarche and genetic/environmental factors, such as BMI.
Although it was previously demonstrated that overweight girls experience earlier pubarche, thelarche, and menarche than those with a normal BMI (5, 19) , there are little data examining age at menarche in girls who develop PCOS. The only exception is in a subset of girls with PCOS born small for gestational age, which later develop early pubarche and menarche (4) . Our data demonstrate a strong inverse relationship between reported weight group during the menarchal age window and age at menarche, consistent with data in the population (5, 19) . Thus, girls with PCOS who report overweight in the pubertal window have an earlier age at menarche, whereas those who are thin have a later age at menarche. Interestingly, our PCOS subjects did not have a low birth weight, consistent with previous studies (6, 20) . However, they did have an earlier reported pubarche independent of current BMI. Thus, weight at both high and low ends during puberty is a predictor of menarchal age in girls who develop PCOS, whereas pubarche appears to be early regardless of weight.
The reported weight group tended to increase from ages 5 -9 to ages 10 -14 years and then stayed higher in age group 15 -19 years in both the PCOS and the control groups. The current rate of obesity was also much greater in the subjects who were overweight from age 10 through age 19 years. These results are consistent with population data indicating that adolescent obesity predicts adult obesity (21, 22) . These fi ndings are also consistent with previous suggestions that overweight in PCOS starts in adolescence or with weight gain from adole scence to adulthood (6, 23) . They also provide validation for the reported weight group in adolescence. Of note, women with PCOS were less likely to have been breastfed, which has been associated with a decreased risk of obesity in epidemiological studies (24) .
As the age at menarche was associated with both reported weight group during puberty and with current BMI, it was possible to examine differences in current phenotype in women with PCOS who had an early vs. a late menarche. Interestingly, despite the higher current weight in women with PCOS who had an earlier age at menarche compared with those with a later age at menarche, there was no difference in current reproductive phenotype as measured by androgen levels, gonadotropin levels, and ovarian morphology. In contrast, metabolic parameters including weight, HDL, and markers of insulin resistance were less favorable in women with PCOS and earlier menarche. The data suggest that there may be two menarchal scenarios in which PCOS develops. The fi rst may be associated with early menarche related to overweight and obesity starting or worsening in puberty. The second may be associated with thinner stature, later age at menarche, and fewer menstrual cycles, refl ecting mainly the arrested follicle development and possibly less estradiol than in the overweight adolescents. Of note, the relationship between later age at menarche and taller stature was and controls (white boxes) as a function of reported weight group at ages 10-14 years. The line represents the median; boxes, the 25th and 75th percent confi dence limits; and the black dots, the age at menarche for outliers. The age at menarche was later in women with PCOS and controls whose weight was less than their peers (a vs. b, p < 0.001) and lower in those whose weight was more than their peers (c vs. b, p < 0.001) than in the group with a similar weight to that of their peers. 1.63 ± 0.01 
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Even when controlled for BMI, age at menarche in women with PCOS was associated with variant rs7759938, located upstream from LIN28B . Of note, other variants in LIN28B are associated with adult height (25) . Further, rs7759938 is (Table 3 continued) associated with growth spurt during early puberty (26) . Lin-28 , the Caenorhabditis elegans homolog of human LIN28B , appears to regulate genes that execute stage-and cell-specifi c development, and overexpression results in developmental abnormalities (27, 28) . Taken together, age at menarche in women with PCOS is infl uenced by the same genetic variant that infl uences age at menarche and pubertal growth in large population studies (7 -9) . The genetic effect is independent of weight in girls with PCOS and may refl ect the somatic growth suggested by previous studies.
We did not demonstrate a relationship between the other LIN28B variant, rs314277, or the chromosome 9q31.2 variant rs2090409 and age at menarche (7, 10) , perhaps related to the power of the current study. Nevertheless, the A allele of rs2090409 was associated with a smaller waist circumference in control subjects. The effect is the opposite one would expect based on the younger age at menarche conferred by the A allele (7, 10 ) and the expected relationship of obesity to younger age at menarche (5, 19) . These fi ndings suggest that the genetic contribution of rs2090409 and waist size may be acting through a mediator different from adiposity.
The study is limited by the retrospective acquisition of the age at menarche, along with weight group at ages 9 -16 years, birth weight, gestational age, and breastfeeding history. Menarche recall is not as remote as in previous studies in which the correlation between documented and recalled menarchal age 30 to 40 years later is as high as r = 0.78. The correlation between reported weight compared with peers at ages 9 -16 years and documented weight, a validated question, is also high among middle-aged women (15, 29) . Further, the correlation between current weight and reported weight group at menarche is very high, as would be expected based on the relationship between adolescent and adult weight (6, 21 -23) . Finally, others demonstrate a strong correlation between recalled and actual birth weight and breastfeeding (20, 30) . The study is also limited by numbers. Nevertheless, the study had 80 % power to detect a relationship between LIN28B and age at menarche at a p < 0.05 assuming that the OR for the effect is the same as that for the population. We did not examine variants associated with BMI and age at menarche (31) , as previous studies have not demonstrated a relationship between PCOS and variants associated with BMI (32) . However, we have demonstrated that rs9939609 in FTO , the variant most closely associated with BMI in Europeans (33) , was not associated with PCOS (34) .
In summary, age at menarche in women with PCOS is infl uenced by both low and high weight compared with peers during puberty but is also subject to genetic infl uence observed in population studies. Specifi cally, those women with PCOS who are lean or of normal weight and carry the C allele at rs7759938 are more likely to have late age at menarche, whereas those who were overweight starting at or before puberty and carry the T allele at rs7759938 are more likely to have an early menarche compared with controls. The fi ndings suggest the possibility that there are two menarchal scenarios resulting in PCOS, one infl uenced by overweight at the time of puberty and another in which weight is lower and menarche later. Further studies are needed to document lifestyle and estradiol or other hormonal differences in these two states at the time at the time of puberty.
